← All trials
NCT04454437
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2020
- Primary completion
- Oct 31, 2021
- Completion date
- Nov 27, 2022
- First posted
- Jul 1, 2020
- Last posted
- Nov 20, 2020
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Everest MedicinesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- ParexelCollaborator
- Medidata SolutionsCollaborator
- IQVIACollaborator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.